SEC Form 4 · accession 0001209191-18-037075
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilmore Neil O'Neill
Officer — SVP & Chief Medical Officer
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $96.23 | Jun 7, 2018 | A | 100,000 | A | — | Jun 7, 2028 | Common Stock | 100,000 | 100,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jun 7, 2018 | A | 12,000 | A | May 23, 2019 | — | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F125% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
- F2Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock.
- F3The restricted stock units will vest on May 23, 2019.